Q1 2025 · 13F-HR
TCG Crossover Management, LLCholdings as filed
Filed 2025-05-14 · accession 0001214659-25-007553
$733.1M
Reported value
38
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 156944100 | CGON | CG ONCOLOGY INC | $89.9M | 12.3% | 3,670,206 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $41.7M | 5.69% | 6,964,375 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $41.6M | 5.67% | 2,890,816 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $39.2M | 5.35% | 2,470,265 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $39.0M | 5.32% | 5,319,148 | Common | SOLE |
| 00370M103 | ABVX | ABIVAX SA AMERICAN DEPOSITARY SHARES | $37.9M | 5.16% | 6,056,596 | Common | SOLE |
| 805111101 | SVRA | SAVARA INC | $34.2M | 4.67% | 12,362,205 | Common | SOLE |
| 26818M108 | DYN | DYNE THERAPEUTICS INC | $27.7M | 3.78% | 2,650,150 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $27.2M | 3.72% | 1,501,624 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $27.0M | 3.68% | 2,898,103 | Common | SOLE |
| 98401F105 | XNCR | XENCOR INC | $26.1M | 3.56% | 2,452,138 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $23.1M | 3.15% | 465,257 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $22.5M | 3.07% | 1,477,593 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $21.7M | 2.96% | 1,005,901 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $21.0M | 2.87% | 5,943,812 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $19.6M | 2.68% | 275,000 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS INC | $19.4M | 2.64% | 3,572,335 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $18.4M | 2.51% | 1,063,000 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $17.1M | 2.34% | 2,801,763 | Common | SOLE |
| 75382E109 | — | RAPT Therapeutics, Inc. | $16.0M | 2.18% | 13,090,200 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $15.1M | 2.06% | 5,250,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $14.7M | 2.01% | 2,761,861 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $14.7M | 2.01% | 10,736,000 | Common | SOLE |
| 20451W101 | CMPS | COMPASS PATHWAYS LTD | $11.0M | 1.51% | 3,858,000 | Common | SOLE |
| 50127T109 | KURA | KURA ONCOLOGY INC | $9.4M | 1.28% | 1,423,642 | Common | SOLE |
| 88427A107 | — | THIRD HARMONIC BIO INC | $8.7M | 1.19% | 2,505,424 | Common | SOLE |
| 82686Q101 | SLN | SILENCE THERAPEUTICS PLC | $8.6M | 1.17% | 3,033,560 | Common | SOLE |
| 00773U207 | AVU0 | ADVERUM BIOTECHNOLOGIES INC | $7.9M | 1.07% | 1,796,482 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $6.7M | 0.91% | 2,676,580 | Common | SOLE |
| 008064107 | — | AEROVATE THERAPEUTICS INC | $5.6M | 0.77% | 2,240,809 | Common | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $5.3M | 0.72% | 584,955 | Common | SOLE |
| 55287L101 | MBX | MBX BIOSCIENCES INC | $4.8M | 0.65% | 650,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $3.9M | 0.53% | 483,000 | Common | SOLE |
| 50015M109 | KOD | KODIAK SCIENCES INC | $3.2M | 0.44% | 1,145,538 | Common | SOLE |
| 640268108 | NKTREUR | NEKTAR THERAPEUTICS | $2.7M | 0.37% | 4,000,000 | Common | SOLE |
| 92332V107 | VTYXUSD | VENTYX BIOSCIENCES INC | $363,624 | 0.05% | 316,195 | Common | SOLE |
| 12674W109 | CABA | CABALETTA BIO INC | $120,211 | 0.02% | 86,795 | Common | SOLE |
| 492327101 | KROS | KEROS THERAPEUTICS INC | $0 | — | 0 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.